Our present healthcare system focuses on treating people when they are ill rather than keeping them healthy. We have been using big data and remote monitoring approaches to monitor people while they are healthy to keep them that way and detect disease at its earliest moment presymptomatically. We use advanced multiomics technologies (genomics, immunomics, transcriptomics, proteomics, metabolomics, microbiomics) as well as wearables and microsampling for actively monitoring health. Following a group of 109 individuals for up to 13 years revealed numerous major health discoveries covering cardiovascular disease, oncology, metabolic health and infectious disease. We have also found that individuals have distinct aging patterns that can be measured in an actionable period of time. Finally, we have used wearable devices for early detection of infectious disease, including COVID-19 as well as microsampling for monitoring and improving lifestyle. We believe that advanced technologies have the potential to transform healthcare and keep people healthy.
Join Michael Snyder, Professor & Chair, Stanford University School of Medicine in this Free Webinar to discuss the use of big data and remote monitoring to transform healthcare today.
Moderated by Neil Spooner, Director, Spooner Bioanalytical Solutions and Co-Founder of the PCSIG,
Speakers
Michael Snyder
Professor & Chair Stanford University School of Medicine
Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. He received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. Dr. Snyder has pioneered the use of “big data” and multiomics to advance scientific discovery and transform healthcare. His laboratory has invented many technologies that are widely used in medicine and research, including methods for characterizing genomes and their products (e.g., RNA-Seq, NGS paired end sequencing, ChIP-Chip and later Chip-Seq, protein arrays, machine learning for disease gene discovery, and wearables for monitoring personal health and exposures). His application of omics and wearables technologies to perform longitudinal profiling of people when they are healthy and ill is transforming medicine and healthcare. Indeed, his laboratory’s recent work to use smartwatches and wearables to detect illness, including infectious disease such as COVID-19, prior to symptom onset is being used by many thousands of people. He has helped colead many large scale projects including ENCODE, HMP, HuBMAP and HTAN. He has cofounded 16 biotechnologies companies, including Personalis, Qbio, January AI, Filtricine, RTHM, Marble Therapeutics and Iollo.
Moderator
Neil Spooner
Director Spooner Bioanalytical Solutions & Chair Patient Centric Sampling Interest Group
Neil is the Founder of Spooner Bioanalytical Solutions, helping companies to integrate biological fluid microsampling, and patient centric sampling and analysis into workflows. He also works with organizations to develop technologies and introduce them to the market. Neil also assists organizations with their understanding of emerging trends in the pharmaceutical industry and bioanalysis. Neil is a Senior Visiting Research Fellow at the University of Hertfordshire, Editor in Chief of the journal, Bioanalysis, Founder of the Patient Centric Sampling Interest Group and Co-Chair of the Reid Bioanalytical Forum. He has published over 70 peer reviewed manuscripts and delivered over 50 podium presentations.
IN ASSOCIATION WITH
OUR SPONSORS
Altasciences: Altasciences is a drug development solution company offering a flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management.
Capitainer: Dried blood spots (DBS) is now quantitative with volumetric control through our microfluidic qDBS technology solution. Precision, accuracy, sample protection and ease of use both at sampling and in the lab are key features for us in all product development.
Celerion: Celerion, a global leader in early clinical research services, conducts First-in-Human, clinical Proof-of-Concept and patient dose response studies, cardiovascular safety and clinical pharmacology research supporting product labeling. With purpose-built, co-located clinic and laboratory facilities and highly automated technology, Celerion provides full study services including clinical study conduct, data management and biometrics, PK/PD analysis, medical writing and bioanalytical services.
Lindus Health: Our mission at Lindus Health is to unleash biology’s century by removing the biggest bottleneck: clinical trials. We are an “anti-CRO” running radically faster, more reliable clinical trials for life-science pioneers.
Mercodia: Mercodia delivers tailored, fit-for-purpose bioanalytical services for preclinical and clinical development. With over 30 years of experience developing ligand binding assays (LBAs), we offer an extensive biomarker portfolio, notably within the field of cardiometabolic disease. With our premium products and services, you are guaranteed the highest performance.
Neoteryx: Neoteryx, the microsampling product brand of Trajan Scientific and Medical, provides remote microsampling tools, such as the Mitra® with VAMS® and hemaPEN® devices, which deliver portable convenience and precision for efficient lab workflows and reliable data. Using these minimally invasive finger-stick microsampling devices paired with multi-omics technologies, researchers can analyze the samples to measure thousands of molecules. Our microsampling solutions have been used to study metabolic markers, immune markers, neurological markers and more to gain deeper insights into human health.
Q2 Solutions: Q2 Solutions, a wholly owned subsidiary and laboratory division of IQVIA, is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository and specimen management, and clinical trial sample and consent tracking solutions. Through its Decentralized Clinical Trials group, Q2 Solutions is at the forefront of patient-centric sampling, offering a variety of self-collection methodologies and is validating multiple assays using micro-samples that are self-collected by study participants.
Synexa Life Sciences: For over 20 years, Synexa Life Sciences has supported large and emerging biopharma customers across the globe to achieve their clinical milestones through the delivery of cutting-edge biomarker and bioanalytical services. Synexa specialises in the development, validation and delivery of a wide range of complex and custom-designed assays across five laboratory locations.
Tasso: Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time.
Veloxity Labs: Veloxity Labs is a CRO focused on LC-MS bioanalysis. Our company is employee owned and operated, and offers start-up times and turn-around times in days by maintaining 80% capacity.